• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Organovo Holdings (NQ: ONVO )

    0.4650 +0.0127 (+2.81%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Organovo Holdings

    Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
    Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024 
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
    From Organovo, Inc.
    Via GlobeNewswire
    CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo Highlights FXR314 Combination Therapy Potential and Plan
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo to Participate in the H.C. Wainwright Global Investment Conference
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo Announces FXR Program
    Lead Molecule Poised for Phase 2 in IBD 
    From Organovo, Inc.
    Via GlobeNewswire
    Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
    From Organovo, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.